In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genomics company WuXi NextCODE raises $75mm in Series B capital; later raises additional $165mm

Executive Summary

WuXi NextCODE Genomics (contract genomics) raised $75mm in its Series B financing round co-led by Temasek and Yunfeng Capital with participation from Amgen Ventures and 3W Partners. The firm will use the proceeds to advance the commercialization of its consumer offerings for the China market, to strengthen its global leadership position in informatics, and to expand its artificial intelligence and deep learning capabilities. The company was formed in January 2015 when WuXi PharmaTech acquired genomics company NextCODE Health. Earlier this year WuXi NextCODE entered into a 15-year collaboration with AbbVie Inc. and Genomics Medicine Ireland to perform population genomics research in Ireland with the goal of discovering and developing new therapies for diseases in the areas of oncology, neuroscience, and immunology.

Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies